Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 21;9(7):e002673. doi: 10.1136/jitc-2021-002673

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Doses and treatment schedules for phase I studies of reovirus and chemotherapy. (A) Clinical trials include reovirus (REO) administered intravenously as a single-agent (REO005) or in combination with chemotherapy: gemcitabine (REO009), docetaxel (REO010), carboplatin and paclitaxel (REO011), and cyclophosphamide (REO012). With the exception of REO009, reovirus was given consecutively for the first 5 days of the treatment cycle. For REO005 and REO012, each cycle lasted 28 days, and for REO009, REO010 and REO011, each cycle lasted 21 days. (B) Blood samples for antibody analysis were collected as indicated by the orange arrows. Reovirus was administered within the first 5 days (days 1–5) of the treatment cycle as indicated by the red arrows. EOS, end of study.